-
Je něco špatně v tomto záznamu ?
Geranylated flavanone tomentodiplacone B inhibits proliferation of human monocytic leukaemia (THP-1) cells
P. Kollár, T. Bárta, V. Závalová, K. Smejkal, A. Hampl,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Free Medical Journals
od 1968 do Před 1 rokem
PubMed Central
od 1968 do 2020
Europe PubMed Central
od 1968 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2002-01-01 do Před 1 rokem
Wiley Free Content
od 1997
- MeSH
- akutní monocytární leukemie MeSH
- antikarcinogenní látky farmakologie MeSH
- cyklin D metabolismus MeSH
- cyklin-dependentní kinasa 2 antagonisté a inhibitory biosyntéza metabolismus MeSH
- cykliny metabolismus MeSH
- down regulace účinky léků MeSH
- flavanony farmakologie MeSH
- G1 fáze účinky léků MeSH
- lidé MeSH
- monocyty cytologie účinky léků metabolismus MeSH
- monoterpeny farmakologie MeSH
- nádorové buněčné linie MeSH
- proliferace buněk účinky léků MeSH
- signální transdukce účinky léků MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND AND PURPOSE: Paulownia tomentosa is a rich source of geranylated flavanones, some of which we have previously shown to have cytotoxic activity. To identify members of this class of compounds with cytostatic effects, we assessed the effects of the geranylated flavanone tomentodiplacone B (TOM B) on cell cycle progression and cell cycle regulatory pathways of THP-1 human monocytic leukaemia cells. EXPERIMENTAL APPROACH: Cell viability was measured by dye exclusion and proliferation by WST-1 assays; cell cycle was monitored by flow cytometry. Regulatory proteins were assessed by immunoprecipitation and kinase assays, and Western blotting. KEY RESULTS: Tomentodiplacone B had no effect during the first 24 h of cell growth at concentrations between 1 and 2.5 µM, but inhibited cell growth in a dose-dependent manner at concentrations of 5 µM or higher. Growth inhibition during the first 24 h of exposure to TOM B was not accompanied by cytotoxicity as cells were accumulated in G1 phase dose-dependently. This G1 phase accumulation was associated with down-regulation of cyclin-dependent kinase 2 activity and also protein levels of cyclins E1 and A2. However, key stress-related molecules (γ-H2AX, p53 and p21) were not induced, suggesting that TOM B acts by directly inhibiting the cyclin-dependent kinase 2 signalling pathway rather than initiating DNA damage or cellular stress. CONCLUSIONS AND IMPLICATIONS: Our study provides the first evidence that TOM B directly inhibits proliferation of human monocytic leukaemia cells, and thus is a potential anticancer agent, preventing leukaemia cells from progressing from G1 phase into DNA synthesis.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12027909
- 003
- CZ-PrNML
- 005
- 20121206122857.0
- 007
- ta
- 008
- 120817s2011 enk f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1111/j.1476-5381.2010.01171.x $2 doi
- 035 __
- $a (PubMed)21175584
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Kollár, Peter $u Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic. kollarp@vfu.cz
- 245 10
- $a Geranylated flavanone tomentodiplacone B inhibits proliferation of human monocytic leukaemia (THP-1) cells / $c P. Kollár, T. Bárta, V. Závalová, K. Smejkal, A. Hampl,
- 520 9_
- $a BACKGROUND AND PURPOSE: Paulownia tomentosa is a rich source of geranylated flavanones, some of which we have previously shown to have cytotoxic activity. To identify members of this class of compounds with cytostatic effects, we assessed the effects of the geranylated flavanone tomentodiplacone B (TOM B) on cell cycle progression and cell cycle regulatory pathways of THP-1 human monocytic leukaemia cells. EXPERIMENTAL APPROACH: Cell viability was measured by dye exclusion and proliferation by WST-1 assays; cell cycle was monitored by flow cytometry. Regulatory proteins were assessed by immunoprecipitation and kinase assays, and Western blotting. KEY RESULTS: Tomentodiplacone B had no effect during the first 24 h of cell growth at concentrations between 1 and 2.5 µM, but inhibited cell growth in a dose-dependent manner at concentrations of 5 µM or higher. Growth inhibition during the first 24 h of exposure to TOM B was not accompanied by cytotoxicity as cells were accumulated in G1 phase dose-dependently. This G1 phase accumulation was associated with down-regulation of cyclin-dependent kinase 2 activity and also protein levels of cyclins E1 and A2. However, key stress-related molecules (γ-H2AX, p53 and p21) were not induced, suggesting that TOM B acts by directly inhibiting the cyclin-dependent kinase 2 signalling pathway rather than initiating DNA damage or cellular stress. CONCLUSIONS AND IMPLICATIONS: Our study provides the first evidence that TOM B directly inhibits proliferation of human monocytic leukaemia cells, and thus is a potential anticancer agent, preventing leukaemia cells from progressing from G1 phase into DNA synthesis.
- 650 _2
- $a antikarcinogenní látky $x farmakologie $7 D016588
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a proliferace buněk $x účinky léků $7 D049109
- 650 _2
- $a cyklin D $x metabolismus $7 D056741
- 650 _2
- $a cyklin-dependentní kinasa 2 $x antagonisté a inhibitory $x biosyntéza $x metabolismus $7 D051357
- 650 _2
- $a cykliny $x metabolismus $7 D016213
- 650 _2
- $a down regulace $x účinky léků $7 D015536
- 650 _2
- $a flavanony $x farmakologie $7 D044950
- 650 _2
- $a G1 fáze $x účinky léků $7 D016193
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a akutní monocytární leukemie $7 D007948
- 650 _2
- $a monocyty $x cytologie $x účinky léků $x metabolismus $7 D009000
- 650 _2
- $a monoterpeny $x farmakologie $7 D039821
- 650 _2
- $a signální transdukce $x účinky léků $7 D015398
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Bárta, Tomáš
- 700 1_
- $a Závalová, Veronika
- 700 1_
- $a Smejkal, Karel
- 700 1_
- $a Hampl, Aleš
- 773 0_
- $w MED00009383 $t British journal of pharmacology $x 1476-5381 $g Roč. 162, č. 7 (2011), s. 1534-41
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/21175584 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m
- 990 __
- $a 20120817 $b ABA008
- 991 __
- $a 20121206122930 $b ABA008
- 999 __
- $a ok $b bmc $g 949951 $s 785255
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2011 $b 162 $c 7 $d 1534-41 $i 1476-5381 $m British journal of pharmacology $n Br J Pharmacol $x MED00009383
- LZP __
- $a Pubmed-20120817/11/03